A vaccine targeting CEA (Yeast-CEA (GI-6207) increased CD4+ and CD8+ T cells and downregulated Tregs in some patients (NCT00924092, no HNSCC patients enrolled) [160]. Here, CEACAM5 is linked to head and neck squamous cell carcinoma.